个人中心 - 老虎社区

紫一軒

IP属地：浙江

帖子 · 9帖子 · 9
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- 紫一軒紫一軒
  ·2024-10-14
  $Akoustis Technologies Inc(AKTS)$
  1,195 评论
  点赞
  分享
  举报
- 紫一軒紫一軒
  ·2022-08-09
  小米没有翻身日了？
  非常抱歉，此主贴已删除
  2,577 评论
  1
  分享
  举报
- 紫一軒紫一軒
  ·2022-03-21
  我还能翻身吗？$小米集团-W(01810)$
  3,523 2
  点赞
  分享
  举报
- 紫一軒紫一軒
  ·2022-03-03
  $Indaptus Therapeutics, Inc.(INDP)$这美股跌得太厉害了吧？
  3,546 1
  点赞
  分享
  举报
- 紫一軒紫一軒
  ·2022-02-07
  我年前把闲钱存入闲钱管家账户913美元，现在打不开管家账户打开交易记录什么都没有？钱到那里去了？请回复我
  3,200 2
  点赞
  分享
  举报
- 紫一軒紫一軒
  ·2021-09-25
  $Indaptus Therapeutics, Inc.(INDP)$这股一跌再跌！主力不显？能否回本？美股，港股全跌！
  3,123 评论
  点赞
  分享
  举报
- 紫一軒紫一軒
  ·2021-09-17
  $Staffing 360 Solutions Inc.(STAF)$这股会上去回本吗？
  3,530 评论
  点赞
  分享
  举报
- 紫一軒紫一軒
  ·2021-08-18
  这篇文章不错，转发给大家看
  BRIEF-Arbutus Authorized To Proceed With Investigational New Drug Application For AB-729
  July 7 (Reuters) - Arbutus Biopharma Corp : * ARBUTUS RECEIVES AUTHORIZATION TO PROCEED WITH AN
  BRIEF-Arbutus Authorized To Proceed With Investigational New Drug Application For AB-729
  2,824 评论
  点赞
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3578613169604460","uuid":"3578613169604460","gmtCreate":1615649972901,"gmtModify":1631174453463,"name":"紫一軒","pinyin":"zy軒ziyi軒","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/cad99049b0a902e540a25f7865ebb037","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":77,"tweetSize":9,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":14,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-3","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"偶像虎友","description":"加入老虎社区1500天","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.04.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"60.06%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"浙江","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":359836398997544,"gmtCreate":1728858597150,"gmtModify":1728858598065,"author":{"id":"3578613169604460","authorId":"3578613169604460","name":"紫一軒","avatar":"https://static.tigerbbs.com/cad99049b0a902e540a25f7865ebb037","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578613169604460","idStr":"3578613169604460"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/AKTS\">$Akoustis Technologies Inc(AKTS)$ &nbsp;</a>","listText":"<a href=\"https://laohu8.com/S/AKTS\">$Akoustis Technologies Inc(AKTS)$ &nbsp;</a>","text":"$Akoustis Technologies Inc(AKTS)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/359836398997544","isVote":1,"tweetType":1,"viewCount":1195,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":684061927,"gmtCreate":1660011033073,"gmtModify":1660011033073,"author":{"id":"3578613169604460","authorId":"3578613169604460","name":"紫一軒","avatar":"https://static.tigerbbs.com/cad99049b0a902e540a25f7865ebb037","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578613169604460","idStr":"3578613169604460"},"themes":[],"htmlText":"小米没有翻身日了？","listText":"小米没有翻身日了？","text":"小米没有翻身日了？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/684061927","repostId":"2257463911","repostType":2,"isVote":1,"tweetType":1,"viewCount":2577,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":637905625,"gmtCreate":1647846356447,"gmtModify":1647846356447,"author":{"id":"3578613169604460","authorId":"3578613169604460","name":"紫一軒","avatar":"https://static.tigerbbs.com/cad99049b0a902e540a25f7865ebb037","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578613169604460","idStr":"3578613169604460"},"themes":[],"htmlText":"我还能翻身吗？<a href=\"https://laohu8.com/S/01810\">$小米集团-W(01810)$</a>","listText":"我还能翻身吗？<a href=\"https://laohu8.com/S/01810\">$小米集团-W(01810)$</a>","text":"我还能翻身吗？$小米集团-W(01810)$","images":[{"img":"https://static.tigerbbs.com/7b39757a4afebc691a8a34fa6987757d","width":"1080","height":"1920"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/637905625","isVote":1,"tweetType":1,"viewCount":3523,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"CN","totalScore":0},{"id":632328420,"gmtCreate":1646265341086,"gmtModify":1646265341086,"author":{"id":"3578613169604460","authorId":"3578613169604460","name":"紫一軒","avatar":"https://static.tigerbbs.com/cad99049b0a902e540a25f7865ebb037","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578613169604460","idStr":"3578613169604460"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/INDP\">$Indaptus Therapeutics, Inc.(INDP)$</a>这美股跌得太厉害了吧？","listText":"<a href=\"https://laohu8.com/S/INDP\">$Indaptus Therapeutics, Inc.(INDP)$</a>这美股跌得太厉害了吧？","text":"$Indaptus Therapeutics, Inc.(INDP)$这美股跌得太厉害了吧？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/632328420","isVote":1,"tweetType":1,"viewCount":3546,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":633575771,"gmtCreate":1644247322712,"gmtModify":1644247322712,"author":{"id":"3578613169604460","authorId":"3578613169604460","name":"紫一軒","avatar":"https://static.tigerbbs.com/cad99049b0a902e540a25f7865ebb037","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578613169604460","idStr":"3578613169604460"},"themes":[],"htmlText":"我年前把闲钱存入闲钱管家账户913美元，现在打不开管家账户打开交易记录什么都没有？钱到那里去了？请回复我","listText":"我年前把闲钱存入闲钱管家账户913美元，现在打不开管家账户打开交易记录什么都没有？钱到那里去了？请回复我","text":"我年前把闲钱存入闲钱管家账户913美元，现在打不开管家账户打开交易记录什么都没有？钱到那里去了？请回复我","images":[{"img":"https://static.tigerbbs.com/caddc33ed96155a5cbfe50f59c138e97","width":"1080","height":"2669"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/633575771","isVote":1,"tweetType":1,"viewCount":3200,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"4095817427637360","authorId":"4095817427637360","name":"反复抄底","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"authorIdStr":"4095817427637360","idStr":"4095817427637360"},"content":"升级到最新版就有显示了。我想知道的是这东西到底买了什么，放进去几个月放了个寂寞。","text":"升级到最新版就有显示了。我想知道的是这东西到底买了什么，放进去几个月放了个寂寞。","html":"升级到最新版就有显示了。我想知道的是这东西到底买了什么，放进去几个月放了个寂寞。"}],"imageCount":1,"langContent":"CN","totalScore":0},{"id":861512648,"gmtCreate":1632523131184,"gmtModify":1632523131184,"author":{"id":"3578613169604460","authorId":"3578613169604460","name":"紫一軒","avatar":"https://static.tigerbbs.com/cad99049b0a902e540a25f7865ebb037","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578613169604460","idStr":"3578613169604460"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/INDP\">$Indaptus Therapeutics, Inc.(INDP)$</a>这股一跌再跌！主力不显？能否回本？美股，港股全跌！","listText":"<a href=\"https://laohu8.com/S/INDP\">$Indaptus Therapeutics, Inc.(INDP)$</a>这股一跌再跌！主力不显？能否回本？美股，港股全跌！","text":"$Indaptus Therapeutics, Inc.(INDP)$这股一跌再跌！主力不显？能否回本？美股，港股全跌！","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/861512648","isVote":1,"tweetType":1,"viewCount":3123,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":885706285,"gmtCreate":1631831900147,"gmtModify":1631831900147,"author":{"id":"3578613169604460","authorId":"3578613169604460","name":"紫一軒","avatar":"https://static.tigerbbs.com/cad99049b0a902e540a25f7865ebb037","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578613169604460","idStr":"3578613169604460"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/STAF\">$Staffing 360 Solutions Inc.(STAF)$</a>这股会上去回本吗？","listText":"<a href=\"https://laohu8.com/S/STAF\">$Staffing 360 Solutions Inc.(STAF)$</a>这股会上去回本吗？","text":"$Staffing 360 Solutions Inc.(STAF)$这股会上去回本吗？","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/885706285","isVote":1,"tweetType":1,"viewCount":3530,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":831946971,"gmtCreate":1629283264693,"gmtModify":1629283264693,"author":{"id":"3578613169604460","authorId":"3578613169604460","name":"紫一軒","avatar":"https://static.tigerbbs.com/cad99049b0a902e540a25f7865ebb037","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3578613169604460","idStr":"3578613169604460"},"themes":[],"htmlText":"这篇文章不错，转发给大家看","listText":"这篇文章不错，转发给大家看","text":"这篇文章不错，转发给大家看","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/831946971","repostId":"2149392484","repostType":2,"repost":{"id":"2149392484","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1625657723,"share":"https://ttm.financial/m/news/2149392484?lang=&edition=full","pubTime":"2021-07-07 19:35","market":"us","language":"en","title":"BRIEF-Arbutus Authorized To Proceed With Investigational New Drug Application For AB-729","url":"https://stock-news.laohu8.com/highlight/detail?id=2149392484","media":"Reuters","summary":"July 7 (Reuters) - Arbutus Biopharma Corp   :   * ARBUTUS RECEIVES AUTHORIZATION TO PROCEED WITH AN ","content":"<html><body><p>July 7 (Reuters) - Arbutus Biopharma Corp   :</p><p>   * ARBUTUS RECEIVES AUTHORIZATION TO PROCEED WITH AN INVESTIGATIONAL NEW DRUG APPLICATION <a href=\"https://laohu8.com/S/IND\">$(IND)$</a> FOR AB-729, ITS PROPRIETARY SUBCUTANEOUSLY-DELIVERED RNAI AGENT</p><p>   * ARBUTUS BIOPHARMA - PHASE 2A TRIAL TO EVALUATE SAFETY &amp; EFFICACY OF AB-729 WITH ONGOING NA THERAPY &amp; SHORT COURSES OF PEG-IFNΑ-2A IN SUBJECTS WITH CHB</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Arbutus Authorized To Proceed With Investigational New Drug Application For AB-729</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Arbutus Authorized To Proceed With Investigational New Drug Application For AB-729\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-07-07 19:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>July 7 (Reuters) - Arbutus Biopharma Corp   :</p><p>   * ARBUTUS RECEIVES AUTHORIZATION TO PROCEED WITH AN INVESTIGATIONAL NEW DRUG APPLICATION <a href=\"https://laohu8.com/S/IND\">$(IND)$</a> FOR AB-729, ITS PROPRIETARY SUBCUTANEOUSLY-DELIVERED RNAI AGENT</p><p>   * ARBUTUS BIOPHARMA - PHASE 2A TRIAL TO EVALUATE SAFETY &amp; EFFICACY OF AB-729 WITH ONGOING NA THERAPY &amp; SHORT COURSES OF PEG-IFNΑ-2A IN SUBJECTS WITH CHB</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ABUS":"Arbutus Biopharma Corporation","NGD":"New Gold"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2149392484","content_text":"July 7 (Reuters) - Arbutus Biopharma Corp   :   * ARBUTUS RECEIVES AUTHORIZATION TO PROCEED WITH AN INVESTIGATIONAL NEW DRUG APPLICATION $(IND)$ FOR AB-729, ITS PROPRIETARY SUBCUTANEOUSLY-DELIVERED RNAI AGENT   * ARBUTUS BIOPHARMA - PHASE 2A TRIAL TO EVALUATE SAFETY & EFFICACY OF AB-729 WITH ONGOING NA THERAPY & SHORT COURSES OF PEG-IFNΑ-2A IN SUBJECTS WITH CHBSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","news_type":1,"symbols_score_info":{"ABUS":0.9,"NGD":1}},"isVote":1,"tweetType":1,"viewCount":2824,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}